Pharmacometrics Consulting Services

A PBPK Framework to Predict Drug Exposure in Malnourished Children

Erik Sjögren¹ and E. Niclas Jonsson¹

¹*Pharmetheus AB, Uppsala, Sweden*

Objectives

To develop and evaluate a physiologically based translational framework for prediction of drug disposition and PK characteristics in children with severe protein energy malnutrition.

Conclusions

The results demonstrate that the proposed PBPK modelling strategy may be appropriate for predictions of drug disposition and PK in malnourished children.





Protein energy malnutrition in children is a global health problem, particularly in developing countries. The effects of nutritional status on body composition and physiological functions may have implications for drug disposition and ultimately affect the clinical outcome in this already vulnerable population. Physiologically based pharmacokinetic (PBPK) modeling can be used to predict the effect of protein starvation as it links physiological changes to pharmacokinetic (PK) consequences. When established, this approach can be used to guide dose recommendations in malnourish pediatric populations were it can be expected that no PK information is available. Still, the absence of detailed information on body composition and the scarce availability of controlled clinical trials in malnourished children, has so far impeded the establishment and evaluation of a generic PBPK model in this population.

Methods

Changes to body composition and plasma protein concentrations due to protein energy malnutrition were derived for adults from the literature and implemented in PK-Sim[®] (v7.4.0) [1-3]. To accommodate the differences between a healthy and a malnourished population in PK-Sim, compiled physiological data were converted to a set of physiology scaling parameters (PSP). Malnourished pediatric populations (MPP) were acquired by applying the PSP to healthy pediatric populations generated via the population algorithm in PK-Sim[®], including maturation of biological systems, e.g., metabolic enzymes and plasma proteins.

Physiology



Clinical data

information and data compilation

Evaluation

A set of PSP was established which, together with the in-built virtual population algorithm in PK-Sim[®], was adopted to generate MPPs. The change in total body weight generated a population with z-score representative for a population with severe malnourished (Figure 2). A representation of changes in physiological parameters for a generic population (males, age = 2 yr, n=100) is shown in Figure 3. Plasma concentration-time profiles, as well as the inter individual variability, in malnourished children were well captured by the model predictions applying the suggested PBPK framework (Figure 4). Adequate predictions of model drug exposure were achieved for all investigated cases (Table 1).



Figure 2. Distribution of body weight and height for a virtual population (males, age=2 yr) before, i.e., healthy (panel A, [n=100]), and after, i.e., malnourished (Panel B, [n=71]), applying proposed scaling strategy to generate a malnourished population. The WHO z-scores for body weight per height are indicated by colored lines.





Figure 3. Distribution of a selection of physiological parameters (organ volumes (liter), hematocrit and relative albumin expression) for a virtual population (males, age=2 yr) before, i.e., healthy (green [n=100]), and after, i.e., malnourished (red [n=71]), applying proposed scaling strategy to generate a malnourished population.





Malnourishment changes Data selection/adoption

Scaling parameters

1) Healthy pediatric population (HPP)

- 1) Healthy pediatric population (HPP) generated from typical adult ID.
- 2) Malnourished pediatric population created by adopting scaling parameters to the HPP removing outlier in BWT/HT (median±1SD).



Figure 1. Project workflow. Physiology scaling parameters established based on publications, PBPK modeling and generation of healthy virtual populations performed in PK-Sim (v7.4.0)

Simulations were performed in PK-Sim[®] for ciprofloxacin, caffeine and cefoxitin based on the information provided in selected reference studies and using developed or adopted drug models [4-9]. Observed and simulated plasma concentration versus time profiles and PK parameters in malnourished pediatric populations were compared to evaluate the aptness of the suggested modelling approach. A prediction error (PE) (predicted/observed) within the range of 0.5-2.0 were considered as adequate predictive performance.

References

Barac-Nieto M et al. Am J Clin Nutr. (1978) Jan;31(1):23-40.
Bosy-Westphal A et al. Int J Obes Relat Metab Disord. (2004) Jan;28(1):72-9.
https://github.com/Open-Systems-Pharmacology
Thuo N et al. J Antimicrob Chemother. (2011) Oct;66(10):2336-45.
http://atper.eu/wp-content/uploads/2015/12/ATPER2013_Wanicha.pdf
Schlender JF et al. Clin Pharmacokinet. (2018) Dec;57(12):1613-1634
Akinyinka OO et al. Eur J Clin Pharmacol. (2000) May;56(2):153-8.
Buchanan et al.Br. J. Clin. Pharmac. (1980) Jun;9(6):623-7
Kampf et al. Antimicrob Agents Chemother. (1981) Dec;20(6):741-6.



Figure 4. Observed and simulated plasma concentration-time profiles after administration of cefoxitin (intra venous, 40 mg/kg), caffeine (oral, 40 mg) and ciprofloxacin (oral, 10 mg/kg) in malnourished children. Simulations were performed for representative virtual populations (n~80) generated with the proposed scaling strategy (average age [years] indicated in plot header). Observations (mean±SD) are displayed as black dots and simulations as geometric mean (blue line) with CI95% (shaded area).

Table 1. Observed and simulated pharmacokinetic parameters (AUC_t, C_{max} and $t_{\frac{1}{2}}$) and prediction error (PE). Observed values are based on mean observations while simulated values represents the geometric mean (SD) of the population.

	AUC _t			C _{max}			t _{1/2}		
Group	Obs.	Pred.	PE	Obs.	Pred.	PE	Obs.	Pred.	PE
Cefoxitin	43	50 (21)	1.17	96	80 (13)	0.83	0.47	1.3 (0.11)	2.77
Caffeine	49	28 (16)	0.57	3.7	3.8 (1.3)	1.03	10	6.8 (1.8)	0.69
Ciprofloxacin (0.5 yr)	7.8	9.3 (4.2)	1.24	2.3	1.5 (0.82)	0.65	-	3 (0.83)	-
Ciprofloxacin (1 yr)	9.7	9.3 (3.9)	0.95	1.8	1.5 (0.84)	0.83	3.7	3.6 (1.1)	0.97
Ciprofloxacin (2 yr)	9.0	10 (3)	1.14	1.5	1.8 (0.78)	1.20	3.0	3.4 (0.79)	1.13
Ciprofloxacin (5 yr)	8.6	11 (2.9)	1.25	1.6	1.7 (0.57)	1.06	2.8	3.3 (1)	1.19
Ciprofloxacin (10 yr)	16	11 (3.8)	0.71	4.5	1.8 (0.87)	0.41	5.7	3.6 (0.92)	0.63